- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05556096
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
April 19, 2024 updated by: Alexion Pharmaceuticals, Inc.
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
254
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Alexion Pharmaceuticals, Inc. (Sponsor)
- Phone Number: 1-855-752-2356
- Email: clinicaltrials@alexion.com
Study Locations
-
-
-
Buenos Aires, Argentina, 1015
- Recruiting
- Research Site
-
Buenos Aires, Argentina, AR-CP 1221
- Recruiting
- Research Site
-
Caba, Argentina, C1192AAW
- Recruiting
- Research Site
-
Caba, Argentina, 1181
- Recruiting
- Research Site
-
Capital Federal, Argentina, C1428AQK
- Withdrawn
- Research Site
-
Rosario, Argentina, S2000BZL
- Recruiting
- Research Site
-
-
-
-
-
Innsbruck, Austria, 6020
- Recruiting
- Research Site
-
Vienna, Austria, 1090
- Not yet recruiting
- Research Site
-
Wels-Grieskirchen, Austria, 4600
- Recruiting
- Research Site
-
-
-
-
-
Barretos, Brazil, 14784-400
- Recruiting
- Research Site
-
Joinville, Brazil, 89202-190
- Recruiting
- Research Site
-
Porto Alegre, Brazil, 90110-000
- Recruiting
- Research Site
-
Ribeirão Preto, Brazil, 14051-140
- Recruiting
- Research Site
-
Salvador, Brazil, 41253-190
- Recruiting
- Research Site
-
Sao Jose Do Rio Preto, Brazil, 15090-000
- Recruiting
- Research Site
-
Sao Paulo, Brazil, 05403-000
- Recruiting
- Research Site
-
São Paulo, Brazil, 0438-002
- Not yet recruiting
- Research Site
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2G3
- Not yet recruiting
- Research Site
-
-
Ontario
-
London, Ontario, Canada, N6A 5A5
- Recruiting
- Research Site
-
Toronto, Ontario, Canada, M5G 2C4
- Not yet recruiting
- Research Site
-
-
Quebec
-
Montreal, Quebec, Canada, H4A 3TA
- Recruiting
- Research Site
-
Quebec City, Quebec, Canada, G1J 1Z4
- Recruiting
- Research Site
-
-
-
-
-
Beijing, China, 100730
- Recruiting
- Research Site
-
Beijing, China, 100034
- Not yet recruiting
- Research Site
-
Changchun, China, 130021
- Recruiting
- Research Site
-
Changsha, China, 410008
- Recruiting
- Research Site
-
Chengdu, China, 610041
- Recruiting
- Research Site
-
Chongqing, China, 400016
- Recruiting
- Research Site
-
Fuzhou, China, 350001
- Recruiting
- Research Site
-
Hangzhou, China, 310020
- Recruiting
- Research Site
-
Hangzhou, China, 310003
- Recruiting
- Research Site
-
Jinan, China, 250014
- Recruiting
- Research Site
-
Qingdao, China, 266103
- Recruiting
- Research Site
-
Shanghai, China, 201107
- Recruiting
- Research Site
-
Suzhou, China, 215006
- Recruiting
- Research Site
-
Wuhan, China, 430030
- Recruiting
- Research Site
-
Xi'an, China, 710000
- Recruiting
- Research Site
-
-
-
-
-
Aalborg, Denmark, 9000
- Recruiting
- Research Site
-
København Ø, Denmark, 2100
- Recruiting
- Research Site
-
-
-
-
-
Angers, France, 49033
- Recruiting
- Research Site
-
Garches, France, 92380
- Recruiting
- Research Site
-
Lille, France, 59037
- Recruiting
- Research Site
-
Marseille, France, 13385
- Recruiting
- Research Site
-
Montpellier Cedex 5, France, 34295
- Recruiting
- Research Site
-
Nice, France, 06000
- Recruiting
- Research Site
-
Paris Cedex 13, France, 75651
- Recruiting
- Research Site
-
Strasbourg Cedex, France, 67098
- Recruiting
- Research Site
-
-
-
-
-
Berlin, Germany, 10117
- Not yet recruiting
- Research Site
-
Düsseldorf, Germany, 40225
- Recruiting
- Research Site
-
Giessen, Germany, 35392
- Not yet recruiting
- Research Site
-
München, Germany, 81675
- Recruiting
- Research Site
-
München, Germany, D-80336
- Recruiting
- Research Site
-
Tübingen, Germany, 72076
- Recruiting
- Research Site
-
Wuerzburg, Germany, 97074
- Recruiting
- Research Site
-
-
-
-
-
Hadera, Israel
- Recruiting
- Research Site
-
Haifa, Israel, 3109601
- Recruiting
- Research Site
-
Petah Tikva, Israel, 4910000
- Recruiting
- Research Site
-
Ramat Gan, Israel, 5266200
- Recruiting
- Research Site
-
-
-
-
-
Bergamo, Italy, 24127
- Recruiting
- Research Site
-
Brescia, Italy, 25123
- Recruiting
- Research Site
-
Firenze, Italy, 50139
- Recruiting
- Research Site
-
Milano, Italy, 20133
- Recruiting
- Research Site
-
Napoli, Italy, 80131
- Recruiting
- Research Site
-
Palermo, Italy, 90127
- Recruiting
- Research Site
-
Roma, Italy, 00168
- Recruiting
- Research Site
-
Rome, Italy, 00189
- Recruiting
- Research Site
-
Treviso, Italy, 31100
- Recruiting
- Research Site
-
Udine, Italy, 33100
- Recruiting
- Research Site
-
-
-
-
-
Chiba-shi, Japan, 260-0877
- Recruiting
- Research Site
-
Fukushima-shi, Japan, 960-1295
- Recruiting
- Research Site
-
Higashimatsuyama, Japan, 355-0005
- Recruiting
- Research Site
-
Hiroshima-shi, Japan, 734-8551
- Recruiting
- Research Site
-
Isehara-shi, Japan, 259-1193
- Recruiting
- Research Site
-
Itabashi-ku, Japan, 173-8610
- Recruiting
- Research Site
-
Kawasaki-shi, Japan, 216-8511
- Recruiting
- Research Site
-
Morioka, Japan, 020-8505
- Recruiting
- Research Site
-
Nagasaki, Japan, 852-8501
- Recruiting
- Research Site
-
Nagoya, Japan, 466-0065
- Recruiting
- Research Site
-
Nagoya-shi, Japan, 467-0001
- Recruiting
- Research Site
-
Ota-ku, Japan, 143-8541
- Recruiting
- Research Site
-
Shinjuku-ku, Japan, 160-8582
- Recruiting
- Research Site
-
Shinjuku-ku, Japan, 160-0023
- Recruiting
- Research Site
-
Shinjuku-ku, Japan, 162-8666
- Recruiting
- Research Site
-
Suita-shi, Japan, 565-0871
- Recruiting
- Research Site
-
-
-
-
-
Busan, Korea, Republic of, 49241
- Recruiting
- Research Site
-
Daegu, Korea, Republic of, 41404
- Recruiting
- Research Site
-
Gwangju, Korea, Republic of, 61469
- Recruiting
- Research Site
-
Seoul, Korea, Republic of, 03722
- Recruiting
- Research Site
-
Seoul, Korea, Republic of, 05505
- Recruiting
- Research Site
-
Seoul, Korea, Republic of, 06351
- Recruiting
- Research Site
-
Seoul, Korea, Republic of, 02841
- Recruiting
- Research Site
-
Seoul, Korea, Republic of, 5030
- Recruiting
- Research Site
-
-
-
-
-
Amsterdam, Netherlands, 1105 AZ
- Recruiting
- Research Site
-
-
-
-
-
Bydgoszcz, Poland, 85-086
- Recruiting
- Research Site
-
Katowice, Poland, 40-123
- Recruiting
- Research Site
-
Kraków, Poland, 31-202
- Recruiting
- Research Site
-
Kraków, Poland, 31-505
- Recruiting
- Research Site
-
Lublin, Poland, 20064
- Recruiting
- Research Site
-
Poznań, Poland, 61-731
- Recruiting
- Research Site
-
-
-
-
-
Almada, Portugal, 2805-267
- Recruiting
- Research Site
-
Porto, Portugal, 4099-001
- Recruiting
- Research Site
-
-
-
-
-
Belgrade, Serbia, 11000
- Recruiting
- Research Site
-
Nis, Serbia, 18000
- Recruiting
- Research Site
-
-
-
-
-
Badalona(Barcelona), Spain, 08916
- Recruiting
- Research Site
-
Córdoba, Spain, 14004
- Recruiting
- Research Site
-
Hospitalet de Llobregat, Spain, 08907
- Recruiting
- Research Site
-
Madrid, Spain, 28034
- Recruiting
- Research Site
-
Madrid, Spain, 28040
- Recruiting
- Research Site
-
Madrid, Spain, 28046
- Recruiting
- Research Site
-
Málaga, Spain, 29010
- Recruiting
- Research Site
-
Pamplona, Spain, 31008
- Recruiting
- Research Site
-
San Sebastián de los Reyes, Spain, 28702
- Recruiting
- Research Site
-
Sevilla, Spain, 41009
- Recruiting
- Research Site
-
-
-
-
-
Lugano, Switzerland, CH-6900
- Recruiting
- Research Site
-
St. Gallen, Switzerland, CH-9007
- Recruiting
- Research Site
-
Zürich, Switzerland, 8091
- Recruiting
- Research Site
-
-
-
-
-
Kaohsiung City, Taiwan, 833401
- Recruiting
- Research Site
-
Tainan City, Taiwan, 70403
- Not yet recruiting
- Research Site
-
Taipei, Taiwan, 23561
- Recruiting
- Research Site
-
Taipei, Taiwan, 11101
- Recruiting
- Research Site
-
-
-
-
-
Atakum, Turkey, 55280
- Recruiting
- Research Site
-
Bursa, Turkey, 16059
- Recruiting
- Research Site
-
Istanbul, Turkey, 34452
- Recruiting
- Research Site
-
Kocaeli, Turkey, 41380
- Recruiting
- Research Site
-
Kütahya, Turkey, 43100
- Recruiting
- Research Site
-
-
-
-
-
Liverpool, United Kingdom, L9 7AL
- Recruiting
- Research Site
-
London, United Kingdom, EC1A 7BE
- Recruiting
- Research Site
-
Oxford, United Kingdom, 0X3 7LE
- Recruiting
- Research Site
-
Sheffield, United Kingdom, S10 2JF
- Not yet recruiting
- Research Site
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85018
- Recruiting
- Research Site
-
-
California
-
Los Angeles, California, United States, 90095-1624
- Not yet recruiting
- Research Site
-
Orange, California, United States, 92868
- Recruiting
- Research Site
-
Rancho Mirage, California, United States, 92270
- Not yet recruiting
- Research Site
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- Research Site
-
Fort Collins, Colorado, United States, 80528
- Recruiting
- Research Site
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Recruiting
- Research Site
-
-
Florida
-
Bradenton, Florida, United States, 34209
- Recruiting
- Research Site
-
Maitland, Florida, United States, 32751
- Recruiting
- Research Site
-
Orlando, Florida, United States, 32804
- Withdrawn
- Research Site
-
Tampa, Florida, United States, 33612
- Recruiting
- Research Site
-
-
Georgia
-
Augusta, Georgia, United States, 30912
- Recruiting
- Research Site
-
Gainesville, Georgia, United States, 30501
- Recruiting
- Research Site
-
Savannah, Georgia, United States, 31406
- Recruiting
- Research Site
-
-
Illinois
-
Springfield, Illinois, United States, 62769
- Recruiting
- Research Site
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- Recruiting
- Research Site
-
-
Kentucky
-
Lexington, Kentucky, United States, 40503
- Recruiting
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Research Site
-
Brighton, Massachusetts, United States, 02135
- Recruiting
- Research Site
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Recruiting
- Research Site
-
East Lansing, Michigan, United States, 48824
- Recruiting
- Research Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89117
- Recruiting
- Research Site
-
-
New York
-
Patchogue, New York, United States, 11772
- Recruiting
- Research Site
-
Rochester, New York, United States, 14620
- Recruiting
- Research Site
-
Syracuse, New York, United States, 13202
- Recruiting
- Research Site
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- Recruiting
- Research Site
-
Durham, North Carolina, United States, 27710
- Recruiting
- Research Site
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Recruiting
- Research Site
-
-
South Carolina
-
North Charleston, South Carolina, United States, 29406
- Recruiting
- Research Site
-
-
Texas
-
McAllen, Texas, United States, 78503
- Not yet recruiting
- Research Site
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Recruiting
- Research Site
-
-
Washington
-
Seattle, Washington, United States, 98122
- Recruiting
- Research Site
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26506
- Recruiting
- Research Site
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53705
- Recruiting
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosis of MG with generalized muscle weakness meeting the clinical criteria defined by Myasthenia Gravis Foundation of America (MGFA) Class II, III or IV
- Positive serological test for autoantibodies against AChR
Exclusion Criteria:
- History of thymectomy, or any other thymic surgery within 12 months prior to Screening
- Untreated thymic malignancy, carcinoma, or thymoma
- History of Neisseria meningitidis infection
- Pregnancy, breastfeeding, or intention to conceive during the course of the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Participants will receive placebo during the 26-week RCT period, after which they will enter the OLE period of the study and receive ALXN1720.
|
Combination product consisting of syringe prefilled with placebo.
|
Experimental: ALXN1720
Participants will receive a weight-based initial (loading) dose of ALXN1720 on Day 1, followed by weight-based maintenance treatment with ALXN1720 on Day 8 and once every week (Q1W) thereafter for a total of 26 weeks.
Following this randomized controlled treatment (RCT) period, all participants will receive ALXN1720 in an open-label extension (OLE) period of 105 weeks.
|
Combination product consisting of syringe prefilled with ALXN1720.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Week 26
Time Frame: Baseline, Week 26
|
Baseline, Week 26
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Quantitative Myasthenia Gravis (QMG) Total Score at Week 26
Time Frame: Baseline, Week 26
|
Baseline, Week 26
|
|
Change From Baseline in Myasthenia Gravis Composite (MGC) Total Score at Week 26
Time Frame: Baseline, Week 26
|
Baseline, Week 26
|
|
Percentage of Responders Based on Reduction of the MG-ADL Total Score at Week 26
Time Frame: Baseline up to Week 26
|
Response is defined as reduction of the MG-ADL total score by >= 3 points from baseline at Week 26.
|
Baseline up to Week 26
|
Percentage of Responders based on Reduction of the QMG Total Score at Week 26
Time Frame: Baseline up to Week 26
|
Response is defined as reduction of the QMG total score by >= 5 points from baseline at Week 26
|
Baseline up to Week 26
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 21, 2022
Primary Completion (Estimated)
August 5, 2025
Study Completion (Estimated)
July 7, 2027
Study Registration Dates
First Submitted
September 23, 2022
First Submitted That Met QC Criteria
September 23, 2022
First Posted (Actual)
September 27, 2022
Study Record Updates
Last Update Posted (Actual)
April 22, 2024
Last Update Submitted That Met QC Criteria
April 19, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Neoplasms
- Autoimmune Diseases of the Nervous System
- Autoimmune Diseases
- Neoplasms by Site
- Neurologic Manifestations
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Neuromuscular Manifestations
- Nervous System Neoplasms
- Paraneoplastic Syndromes, Nervous System
- Paraneoplastic Syndromes
- Neuromuscular Junction Diseases
- Muscle Weakness
- Myasthenia Gravis
Other Study ID Numbers
- ALXN1720-MG-301
- 2022-000460-21 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Generalized Myasthenia Gravis
-
Assiut UniversityRecruitingNervous System Diseases | Autoimmune Diseases of the Nervous System | Thymoma | Myasthenia Gravis | Neuromuscular Junction Diseases | Myasthenia Gravis, Generalized | Myasthenia Gravis Crisis | Myasthenia Gravis, Ocular | Myasthenia Gravis, Juvenile Form | Thymus Hyperplasia | Myasthenia Gravis With Exacerbation... and other conditionsEgypt
-
Alexion Pharmaceuticals, Inc.CompletedMyasthenia Gravis | Myasthenia Gravis, Generalized | Myasthenia Gravis, Juvenile FormUnited States, Japan, Netherlands
-
Catalyst Pharmaceuticals, Inc.CompletedMyasthenia Gravis, GeneralizedUnited States
-
COUR Pharmaceutical Development Company, Inc.Not yet recruitingMyasthenia Gravis | Generalized Myasthenia | AChR Myasthenia Gravis | MuSK MGUnited States
-
Cabaletta BioNot yet recruitingGeneralized Myasthenia Gravis (gMG)
-
argenxRecruiting
-
Kyverna TherapeuticsNot yet recruitingGeneralized Myasthenia Gravis | Myasthenia Gravis
-
UCB Biopharma SRLNot yet recruitingGeneralized Myasthenia Gravis
-
Tang-Du HospitalRecruitingMyasthenia Gravis, GeneralizedChina
-
Alexion Pharmaceuticals, Inc.RecruitingGeneralized Myasthenia Gravis | gMGSpain, Italy, United States, France, Switzerland, Serbia, Japan, Netherlands
Clinical Trials on ALXN1720
-
Alexion PharmaceuticalsCompletedHealthyUnited Kingdom
-
Alexion Pharmaceuticals, Inc.ParexelRecruitingHealthy Adult ParticipantsCanada, United Kingdom
-
AlexionCompletedProteinuriaKorea, Republic of